Illumina, Henry Ford Health partner to study impact of genomic testing in heart disease
Sundry Photography/iStock Editorial via Getty Images

Illumina (NASDAQ:ILMN) and Detroit metro area-based not-for-profit organization, Henry Ford Health are partnering to assess the impact of comprehensive genomic testing in cardiovascular disease.
The first study under the new partnership, CardioSeq, launched today and will include 1500 patients receiving care from the Division of Cardiovascular Medicine at Henry Ford, according to the company.

Illumina noted that the Lisa and Christopher Jeffries Center for Precision Medicine and the Center for Individualized and Genomic Medicine Research at Henry Ford will undertake a series of implementation and clinical studies that will investigate the use of next-generation sequencing tests, including whole-genome sequencing (WGS), to test their impact on clinical care.
The WGS test used in CardioSeq will screen each patient for more than 200 genetic causes of cardiovascular disease and secondary findings genes, which are linked with known inherited conditions for which interventions are available to mitigate onset or severity of clinical outcome, the company added.